This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

B. Riley Securities Reaffirms Their Buy Rating on Inogen (INGN)

Tipranks - Tipranks - Fri Jan 23, 4:16AM CST

In a report released yesterday, Anderson Schock from B. Riley Securities reiterated a Buy rating on Inogen, with a price target of $14.00. The company’s shares closed yesterday at $6.36.

Claim 50% Off TipRanks Premium

According to TipRanks, Schock is a 2-star analyst with an average return of 2.9% and a 53.33% success rate. Schock covers the Healthcare sector, focusing on stocks such as Inogen, InfuSystem Holdings, and OptimizeRx.

Currently, the analyst consensus on Inogen is a Moderate Buy with an average price target of $13.00, which is a 104.40% upside from current levels. In a report released on January 12, Needham also reiterated a Buy rating on the stock with a $12.00 price target.

See the top stocks recommended by analysts >>

Based on Inogen’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $92.39 million and a GAAP net loss of $5.29 million. In comparison, last year the company earned a revenue of $88.83 million and had a GAAP net loss of $5.96 million

Read More on INGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).